Loading clinical trials...
Loading clinical trials...
The Long-Term Safety and Tolerability of ABT-089 in Adults With Attention Deficit-Hyperactivity Disorder (ADHD): An Open-Label Extension Study for Subjects Completing Study M10-346
The objective of this study is to evaluate the long-term effects and tolerability of ABT-089 in adults with Attention-Deficit/Hyperactivity Disorder (ADHD).
Age
18 - 60 years
Sex
ALL
Healthy Volunteers
No
Site Reference ID/Investigator# 8315
Lafayette, California, United States
Site Reference ID/Investigator# 8306
Jacksonville, Florida, United States
Site Reference ID/Investigator# 8308
Orlando, Florida, United States
Site Reference ID/Investigator# 8314
Overland Park, Kansas, United States
Site Reference ID/Investigator# 8307
Farmington Hills, Michigan, United States
Site Reference ID/Investigator# 8318
Troy, Michigan, United States
Site Reference ID/Investigator# 8309
Eugene, Oregon, United States
Site Reference ID/Investigator# 8316
Portland, Oregon, United States
Site Reference ID/Investigator# 8310
Memphis, Tennessee, United States
Site Reference ID/Investigator# 8319
Virginia Beach, Virginia, United States
Start Date
May 1, 2008
Primary Completion Date
October 1, 2008
Completion Date
October 1, 2008
Last Updated
January 21, 2013
117
ACTUAL participants
ABT-089
DRUG
Lead Sponsor
AbbVie (prior sponsor, Abbott)
NCT06577779
NCT07379359
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and ConditionsNCT07044609